RIGL stock news

RIGL stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

12 wire items

2026-10-29 12:05:00 UTC#536997newconfirmedpress release

Rigel Pharmaceuticals to report Q3 2026 financial results on November 5, 2026

pr newswireimportance 0.30trust 1.00Rigel Pharmaceuticals, Inc. 0

2026-10-19 14:50:11 UTC#481305newconfirmednews

HC Wainwright reiterates Buy rating on Rigel Pharmaceuticals, maintains $85 price target

tradingviewimportance 0.40trust 0.60H.C. Wainwright & Co. +0.20Rigel Pharmaceuticals, Inc. +0.50Pralsetinib +0.30+2 entities

2026-10-19 12:05:00 UTC#480217newconfirmedpress release

Rigel Pharmaceuticals reports 53% response rate for GAVRETO in RET fusion-positive solid tumors at ESMO 2026

pr_newswireimportance 0.40trust 0.90Rigel Pharmaceuticals, Inc. +0.40pralsetinib +0.40European Society for Medical Oncology +0.20+2 entities

2026-09-15 14:40:38 UTC#314667newconfirmednews

Rigel Pharmaceuticals (RIGL) highlights VEPPANU launch and R289 pipeline progress as key growth drivers

quartrimportance 0.40trust 0.50Rigel Pharmaceuticals, Inc. +0.50VEPPANU +0.60R289 +0.40

2026-08-14 17:47:00 UTC#179480newconfirmednews

H.C. Wainwright & Co. maintains Buy rating on Rigel Pharmaceuticals (RIGL)

dow_jonesimportance 0.30trust 0.60Rigel Pharmaceuticals, Inc. +0.20H.C. Wainwright & Co., LLC +0.20

2026-08-05 02:10:48 UTC#126963newconfirmednews

Rigel Pharmaceuticals projects 2026 revenue of $285M-$295M, sets mid-August VEPPANU launch

seeking alphaimportance 0.50trust 0.70Rigel Pharmaceuticals, Inc. +0.50VEPPANU +0.60

2026-08-04 22:11:20 UTC#126185duplicateconfirmednews

Rigel Pharmaceuticals Q2 2026 results show 14% YoY sales growth and raised revenue guidance

quartrimportance 0.30trust 0.50Rigel Pharmaceuticals, Inc. +0.50Tavalisse +0.40Rezlidhia +0.40+1 entities

2026-08-04 21:01:27 UTC#125794duplicateconfirmednews

Rigel Pharmaceuticals reports Q2 2026 adjusted EPS of $0.88 and revenue of $78.7 million

reutersimportance 0.30trust 0.90Rigel Pharmaceuticals, Inc. +0.40

2026-08-04 20:27:16 UTC#125464newconfirmednews

Rigel Pharmaceuticals Q2 GAAP EPS $0.88 beats by $0.11, Revenue $78.7M beats by $23.43M

seeking alphaimportance 0.50trust 0.90Rigel Pharmaceuticals, Inc. +0.60

2026-08-03 11:01:07 UTC#116162newforecastnews

Rigel Pharmaceuticals (RIGL) Q2 2026 Earnings Preview: Analysts Forecast $55.27M Revenue and $0.09 EPS

tradingviewimportance 0.30trust 0.60Rigel Pharmaceuticals, Inc. 0

2026-07-28 11:01:18 UTC#87127newconfirmednews

Rigel Pharmaceuticals (RIGL) Q2 2026 Earnings Preview: $55.27M Revenue and $0.09 EPS Expected

tradingviewimportance 0.40trust 0.70Rigel Pharmaceuticals, Inc. 0

2026-07-06 11:19:44 UTC#2288newconfirmednews

Rigel Pharmaceuticals Names Alison L. Hannah CMO; R289 Trial Progresses

tradingviewimportance 0.40trust 0.80Rigel Pharmaceuticals, Inc. +0.20Alison L. Hannah +0.10R289 +0.30+1 entities